FDA partners with university on biopharmaceutical manufacturing

Published: 14-Aug-2019
Regulatory Pharmaceutical

Delaware University and the FDA will have the ability to collaborate in a pre-competitive environment

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware (US), on behalf of NIIMBL, has entered into a Collaborative Research and Development Agreement (CRADA) with the Food and Drug Administration (FDA). The FDA and NIIMBL will have the ability to collaborate in a pre-competitive environment to strengthen research, innovation, training, and collaboration in the biopharmaceutical manufacturing industry.

"We are increasingly seeing the potential for advanced manufacturing innovations that can improve drug quality, help address shortages of medicines, speed time-to-market, and support personalised medicine through technologies including 3D printing and continuous manufacturing," said Acting FDA Commissioner, Ned Sharpless. "These technologies can also help the US prepare for public health emergencies by rapidly scaling manufacturing capabilities for vaccines and other medical countermeasures. FDA is taking many steps, including this public-private partnership with NIIMBL, to encourage and help realize the potential of advanced manufacturing: issuing guidance on emerging technologies, approving products made with these technologies, and advancing regulatory science."

This CRADA will enable FDA and NIIMBL to support investments in regulatory science research and training needed to foster advanced manufacturing innovations in areas such as continuous manufacturing, on-demand manufacturing, and advanced process control technologies, among others. Ultimately, advancements in these areas will help increase NIIMBL's national impact by enhancing patient access to new and improved medicines.

"Biopharmaceuticals are more challenging to manufacture than traditional pharmaceuticals and NIIMBL seeks to enhance patient access by innovating the biopharmaceutical manufacturing technologies and processes. This CRADA establishes a framework for FDA engagement in NIIMBL projects and initiatives that strengthens the existing NIIMBL-FDA relationship and supports the development of advanced biopharmaceutical manufacturing innovations," says Kelvin Lee, NIIMBL Institute Director.

  • Companies:
  • US Food and Drug Administration (FDA)
  • The National Institute for Innovation in Manufacturing Biopharmaceutic
See more

You may also like

Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

Read more
The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. Optimising the blending of flow aids in powder formulations Flow aids are used routinely in pharmaceutical manufacturing to enhance the process performance of powder blends and safeguard the critical quality attributes of finished products
  4. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Manufacturing

FDA releases guidance to clarify guidelines for 'remanufacturing' devices that need maintenance or repair

The guidelines includes information on reusable product labelling, what it classifies as 'remanufacturing' and how companies can ensure products follow guidelines after multiple uses
Manufacturing

What's in an FDA approval? How a start-up company gets its drug to market

The FDA wields a supreme amount of power in the regulatory realm of the pharmaceutical industry. For smaller start-ups or those newer to the industry, navigating the compliance pathways can prove a daunting task
Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory

Sequana submits IND application for heart failure treatment

The IND application includes data from the previously reported GLP animal and Phase 1 CHIHUAHUA studies
Regulatory

FDA grants marketing approval for safety syringes

Zephyrus' needle system contains an internal mechanism that retracts the needle inside the syringe after activation
Regulatory

FDA releases final guidance for upcoming biological product transition

The BPCI Act requires that a marketing application for a “biological product” must be submitted as a biologics license application
Subscribe now